Gyre Therapeutics, Inc. Share-based Payment Arrangement, Accelerated Cost
Gyre Therapeutics, Inc. (GYRE) reported Share-based Payment Arrangement, Accelerated Cost of $278.00 thousand for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2015-07-31
- Gyre Therapeutics, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2015-06-30 was $278.00K.
- Gyre Therapeutics, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2015-03-31 was $420.00K.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month |
|---|---|---|
| 2015-06-30 | $278.00K 10-Q · filed 2015-07-31 | $698.00K 10-Q · filed 2015-07-31 |
| 2015-03-31 | $420.00K 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |